Rockwell Medical Technologies (RMTI) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Rockwell Medical Reports Third Quarter 2015 Results
November 9, 2015 4:01 PM ESTWIXOM, Mich., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the third quarter of 2015.
Q3 2015 Financial Highlights
Sales were $14.4 million, $0.6 million or 4.6% higher than the third quarter of 2014. Gross profit was $2.5 million, a 10.3% increase over Q3 2014. Gross profit margins increased to 17.4% compared to 16.5% in Q3 2014. SG&A expense was $3.8 million, a decrease of... More